European guidelines indicate the importance of the evaluation of global cardiovascular risk (CVR) to determine the management of the hypertensive patients (EH). However, in primary care, the diagnostic work-up (PCD) only includes the metabolic risk factors. The aim of this study was to assess the importance of microalbuminuria (MA) and echocardiogram (ECHO) in the process of risk stratification, and the number of patients to be treated with drugs at diagnosis. In total, 155 nontreated EH were included in the study. Blood pressure, a lipid profile and plasma glucose (LG) were determined after an overnight fast. MA was evaluated with dipstick MICRALTEST, and in those patients with two positive results, it was measured again in two 24-h urine samples and was considered positive (MA þ ) if the average was 430 mg/24 h. Left ventricular mass index was calculated and values 4125 g/m 2 were considered as LV hypertrophy (LVH þ ). When the patients were stratified according to PCD, 22 had to be treated with drugs. When MA, ECHO and both tests used together were added to the risk evaluation, the number of patients to be treated were 42, 51 and 64, respectively (Po0.001 vs PCD). It is mainly in patients who have moderate cardiovascular risk that risk changes, whereas risk hardly changes in those having low and very high risk. In conclusion, in EH with moderate risk, measurement of MA, due to its easy availability and low cost, seems to be a cost effective screening test to avoid the underestimation of the CVR.
Introduction
Arterial hypertension is one of the main cardiovascular risk (CVR) factors. In addition, it has been well-established that controlling blood pressure (BP) significantly delays the presentation of cardiovascular incidents in the hypertensive patient.
Given that these CVR factors are frequently grouped in these patients, a situation that increases absolute CVR, it seems reasonable, as recommended by the European Society of Hypertension-European Society of Cardiology guidelines for the treatment of arterial hypertension (ESH-ESC 2003), 1 to evaluate absolute CVR of the hypertensive patient. To do so, BP grade, presence of other associated CVR factors, presence of target organ damage and clinical history or evidence of cardiovascular disease should be assessed. This evaluation has different objectives. To determine objective BP values, establish when to initiate drug treatment, discover the need to use specific drugs and add other therapeutic or preventive measures in each patient individually. Once the evaluation is concluded, patients who have high or very high CVR (among them patients with grade 3 hypertension or diabetics) are candidates for drug treatment immediately.
CVR of most of the hypertensive patients is diagnosed and evaluated in Primary Health Care (PHC). Risk stratification in this health care level is generally conducted by only evaluating the classical CVR factors because of the limited accessibility to other more complex and expensive diagnostic tests. This usual approach may underestimate the risk of the patients and raises the question of how far the evaluation of hypertensive subjects may go to reasonably know their CVR and the therapeutic attitude to adopt.
The present study aims to assess the impact of a more exhaustive search of target organ lesion, by measuring microalbuminuria (MA) (a test that is easy to perform and not expensive), echocardiogram (ECHC) and both tests used together in the initial evaluation of a cohort of untreated hypertensive patients. Parallelly, the importance of diabetes mellitus as a parameter determining immediate indication of drug treatment in hypertensive patients was studied.
Objectives
To assess the impact of MA detection and the presence of left ventricular hypertrophy by ECHO in the assessment of CVR of 155 untreated essential hypertensive patients and in the decision to initiate drug treatment immediately. In the second place, to determine how many should be treated with drugs on diagnosis due to their diabetic disease.
Methods

Subjects
All patients with untreated essential HBP who were seen for a 1-year period by 20 PHC physicians from Health Centers of the Madrid Community and who fulfilled the study inclusion criteria and agreed to participate in it were selected. Patients selected had to be between 18 and 75 years old, had recently been diagnosed with HBP without present treatment or, if they had been previously diagnosed with HPB and had received some previous treatment, had not undergone treatment for at least 12 weeks. Furthermore, the patients had to sign an informed consent to participate in the study. Patients diagnosed with secondary HBP, those with established antihypertensive treatment and those diagnosed with type 1 diabetes mellitus were excluded from the study.
A total of 155 patients who fulfilled the inclusion criteria agreed to participate in the study. In all, 31 (20%) of the patients included had been diagnosed of HBP previously and 15 of them had had some type of treatment in the past, this being either dietary or pharmacological, which they later discontinued. The remaining 80% (124) were diagnosed of HBP when enrolling in the study.
Methods
The usual and common evaluation of hypertensive patient in Primary Health Care was performed in all the patients. This included a complete clinical history, detailed physical examination, 12-lead standard ECHO and blood analysis with measurement of fasting glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, creatinine, serum uric acid, and, finally, urine sediment. In addition to this routine assessment, detection of target organ lesion was performed in all the patients by MA test in urine and ECHO.
Electrocardiogram
A standard 12-lead ECG was conducted in all the patients to assess presence of left ventricular hypertrophy, defined by Sokolow criteria (SV1 þ rV5 or V6)438 mm.
Microalbuminuria
MA was measured in all the patients with MI-CRALTEST II reactive strips for three consecutive days and MA in 24-h urine if two of the three previous measurements were positive. The MA test was considered positive when urinary elimination of albumin was 20-200 mg/min or 30-300 mg in 24 h.
Echocardiogram
2D guided M-mode ECHOs (Hewlett-Packard 5500, Andover, MA, USA) were obtained with the patients lying in the left lateral position with the head elevated 301. The transducer was placed in the third or fourth intercostals space, and the measurement was performed distal to the tip of the mitral leaflets for five consecutive cycles. The interventricular septum thickness (IVS), posterior wall thickness (PWT) and left ventricular diastolic internal dimension (LVIDd) were measured at the peak of the QRS complex on a simultaneously recorded ECHO according to the Penn convention. 2 Left ventricular mass was calculated using Devereaux formula divided by body surface area in square meters to obtain LVMI. 2 LVH was defined as a LVMI4125 g/m 2 because of the well-documented prognostic value of such a limit in hypertensive patients. 3 Relative wall thickness (RWT) was calculated by two PWT divided by LVIDd.
All ECHOs were recorded and readings were performed by two trained sonographists who had no knowledge of the subjects' characteristics. The intraobserver variability of LVMI, assessed as the difference between two measurements of the same registration, was o1%.
CVR stratification Absolute CVR grade was defined by the 2003 European guidelines (ESH-ESC).
1 In this, the estimation of suffering cardiovascular events in the future is based on the presence of risk factors such as age, gender, smoking habit, presence of dyslipaemia, family background of premature cardiovascular disease, presence of diabetes or target organ damage and clinical history or evidence of cardiovascular or renal disease. 
Results
The clinical characteristics of the 155 patients are shown in Table 1 In regards to other risk factors 54.8% had dyslipaemia according to the stratification of risk criteria of the last European guidelines of High Blood Pressure (TC4250 mg/dl, LDL4155 mg/dl or HDLo40 mg/dl in men and o50 mg/dl in women); 30.3% smoked; 38.1% were obese (BMI X30 kg/m 2 ); 11.6% had family history of premature cardiovascular disease (at age o55 years in men and o65 years in women); and 6.5% (10 patients) had type 2 diabetes. No patient had elevation of serum creatinine (41.3 mg/dl in men and 1.2 mg/dl in women). None had suffered a previous cardiovascular event. A total of 24 patients (15%) had MA and 3.9% of the patients had electrocardiographic signs of LVH while the prevalence of LVH by ECHO was 21.3%. There were no significant differences regarding gender in the distribution of risk factors of the sample, except for tobacco (Po0.001), its consumption being greater in men.
When the prevalence of risk factors was studied by age groups, there was only a statistically significant association in the prevalence of LVH with age, so that an increase of LVH was observed as age increased (P ¼ 0.016). Prevalence of MA was significantly greater among men (75%) than in women (25%) (P ¼ 0.06), without finding a statistically significant relationship with age or BP grade.
Influence of MA and ECHO in assessment of global CVR When patients were stratified according to a routine evaluation, 34 of the 155 (22%) were classified as having low added CVR, 99 (63.8%) moderate risk; 18 (11.6%) high risk and four (2.5%) very high risk.
When MA was added to the routine risk evaluation, 20 patients (12.9%) (six low risk and 14 moderate risk) changed to high or very high risk. When the ECHO was added to the usual evaluation, 29 patients (18.7%) (seven from low risk patients and 22 from moderate risk ones) changed to highvery high risk. Furthermore, when risk was evaluated using the two techniques together besides the routine evaluation, 42 patients (27%) changed to high-very high risk (11 from low risk and 31 from moderate risk) (Figure 1 (Figure 2) .
It is important to stress that patients with moderate CVR are mainly those who change risk, having a greater risk when tests are performed aimed at detecting target organ lesion, whereas those having low and very high risk hardly change their risk.
When patients were stratified according to the public health care routine evaluation without considering DM, only 11 patients were to be treated, whereas when the concomitant presence of DM was considered, 22 needed to be treated, that is, the number of patients to be treated doubled. In the patients in whom MA was added to the risk evaluation, if DM was not evaluated, 33 would be treated, whereas if it was evaluated, 42 would have been treated. In patients in whom ECHO was performed, without assessing DM, 40 patients would be treated, whereas when it was evaluated, 51 would be treated. If both MA and ECHO were performed without considering DM, 63 patients would be treated versus 64 that would be treated when evaluating DM.
Discussion
The present study shows that the evaluation of CVR in a cohort of untreated hypertensive patients is strongly influenced by the use of diagnostic tests aimed at detecting the presence of target organ lesion and that this stratification has a significant impact when deciding the onset of drug treatment in some of these patients. The presence of high-very high CVR according to the 2003 ESH-ESC is an indication for immediate onset of drug treatment. On the other hand, it may be an indication of more aggressive interventions on other CVR factors associated with HBP. 1 Furthermore, it has been verified that the identification and treatment of elevated risk patients improve cost-effectiveness of antihypertensive treatment for any reduction grade of the BP. 4 The results of the present study demonstrate the great importance of diagnosing diabetes mellitus in hypertensive patients. The search for DM in patients who will undergo routine evaluation only has special importance because 50% of the recently diagnosed hypertensive patients would go untreated.
Considering that the unknown prevalence of type 2 DM in Spain varies between 5.6% 5 and 10.3% 6, 7 and the importance that its diagnosis shows in our study when deciding the treatment of the hypertensive patient, it seems reasonable to consider up to what point the presence of diabetes should be investigated in hypertensive patients. In this sense, in the AVANT study 8 after performing oral glucose tolerance test (OGTT) in 420 hypertensive patients, 34% of them had carbohydrate metabolism disorders unknown up to that time (22.5% carbohydrate intolerance and 11.5% newly diagnosed type 2 diabetes). This means that the diagnoses of diabetes mellitus were doubled. Similar data were obtained in the Salmasi et al.
9 study in which the OGTT was performed in 99 hypertensive patients without known DM, showing that 58% had carbohydrate metabolism disorders (16.1% impaired fasting glucose, 18.1% carbohydrate intolerance and 24.4% newly diagnosed type 2 diabetes). In these circumstances, it seems reasonable to recommend OGTT in Cardiovascular risk and target organ damage M Luque et al those patients in whom more tests are not going to be performed to establish CVR. Regarding MA, although the evidence indicates that it is a strong predictor of cardiovascular morbidity-mortality even in the absence of diabetes mellitus and that both the recommendations of the ESH-ESC 2003 1 and the JNC VII 10 guidelines recognize its value in hypertensive patients, its measurement is not routinely performed in the clinical practice when initially evaluating the hypertensive patient. When MA was measured in the present study, 20 patients (12.9%) changed from low-moderate risk to high-very high risk. This implied that drug treatment had to be initiated immediately in all of them, there being a statistically significant difference between the number of patients to treat with routine assessment and the number that had to be treated when adding MA (Po0.005). Similar results were obtained in the Viazzi et al.
11 study. They also demonstrated that MA was one of the most cost-effective tests in risk stratification in hypertensive patients, recommending it as a screening test, especially as a first step in the large scale evaluation of hypertensive patients.
The ECHO allows us to detect the presence of LVH with greater sensitivity than the electrocardiogram performed in the initial assessment of the hypertensive patient. LVH, as MA, is a potent predictor of CVR. However, and owing to its cost, its routine use has been questioned as an initial routine evaluation method in asymptomatic patients. In the present study, the ECHO made it possible to detect 17.4% of LVH that would not have been diagnosed with the electrocardiogram. As a result of this, 29 patients (18.7%) changed from low-moderate risk to highvery high risk; thus it was being necessary to initiate drug treatment immediately. These results agree with those of other studies that obtained similar results, verifying how the performance of an ECHO to detect LVH presence deeply influences the stratification of CVR and, consequently, the indication of immediate onset of antihypertensive drugs. Thus, in a recent study performed with 1322 hypertensive patients who did not need to be treated with drugs in an initial assessment, Schillaci et al. 12 showed how the performance of the ECHO changed the risk in 29% of them. These became patients who should receive drug treatment. These authors also demonstrated that the detection of LVH in the ECHO is associated with twice the risk of suffering a CV event in subjects classified as low or moderate risk in the routine clinical evaluation. Cuspidi et al. study found that 22% of the hypertensive patients changed from low-moderate risk to high-very high risk with the performance of ECHO.
This present study showed that when both MA and ECHO were performed, 42 more patients needed to be treated than when only the initial assessment was considered, 22 patients more than when this was performed with MA (Po0.008) and 13 more than with the routine assessment and ECHO alone. These results agree with those obtained by Cerasola et al.
14 In their study, when both the MA and ECHO were applied to 312 hypertensive patients 75 (25%), more patients had to be treated than when only the usual assessment was conducted. The performance of more diagnostic tests and their joint assessment help to calculate global CVR of hypertensive patients more accurately.
The data obtained in our study indicate that knowledge of the presence of the target organ damage provided by both MA and the ECHO, in addition to its prognostic value, deeply influences CVR stratification and, consequently, the therapeutic approach of each patient (indicating the onset of treatment with antihypertensive drugs). The routine evaluation of CVR carried out in PHC may lead to underestimating the risk of hypertensive patients, classifying many of them with a CVR lower than that corresponding to them. The results obtained, together with those of other studies that were similar, make it possible to recommend the performance of tests to detect target organ lesion only in the subgroup of patients who are in moderate risk after a usual evaluation. Owing to its low cost and ease of performance, MA may be an attractive and costeffective screening test in the first step of large scale evaluation of hypertensive patients.
One doubt arises when the MA test is negative, this being, discovering in which patients an ECHO should be performed in the initial assessment to detect those with elevated risk and indication of immediate drug treatment. This study shows that 26 of the 131 patients with negative MA had a positive
What is known about the topic K Patients with hypertension frequently have other coexisting cardiovascular risk (CVR) factors and; therefore, a total CVR evaluation has been recommended in these patients.
1
K The usual evaluation of these patients in primary health care does not include the assessment of target organ damage. 15 What this study adds K The routine evaluation of CVR carried out in Primary Health Care (PHC) may lead to underestimating the risk of hypertensive patients, classifying many of them with a CVR lower than that corresponding to them. K In the present study, with the usual approach performed in PHC, drug treatment should have been initiated in 22 patients (14.1%). When microalbuminuria (MA) was measured, 20 patients (12.9%) changed from low-moderate risk to high-very high risk, and drug treatment had to be initiated immediately in all of them. K Those patients who, after this first assessment, have a low and above all moderate CVR should be measured for MA as a first evaluation of the presence of target organ damage, since this is an easy to perform and cost-effective test within the reach of all PHC professionals. 15 who found that the performance of an ECHO may be especially useful in patients who, after an initial assessment that included MA, were classified as having moderate CVR. In this group, 40% were reclassified to high risk according to the ECHO results. The analysis of these data makes it possible to recommend the performance of an ECHO in the initial assessment of those hypertensive patients who, after routine evaluation, had moderate CVR, but without evidence of target organ lesion (in whom the MA test was negative).
In conclusion, in the initial study of all the recently diagnosed hypertensive patients, their global CVR should be evaluated, giving special attention to the diagnosis of diabetes. Those patients who, after this first assessment, have a low and above all moderate CVR should be measured for MA as a first evaluation of the presence of target organ damage, as this is an easy to perform and costeffective test at the reach of all PHC professionals. If the result of the MA test is negative, an ECHO should be performed in those patients who have moderate CVR, that is, those with other risk factors, but without evidence of target organ lesion.
